InflaRx (IFRX)
(Delayed Data from NSDQ)
$1.45 USD
+0.05 (3.57%)
Updated May 16, 2024 04:00 PM ET
After-Market: $1.46 +0.01 (0.69%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IFRX 1.45 +0.05(3.57%)
Will IFRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IFRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IFRX
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing
IFRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why
Other News for IFRX
InflaRx’s Promising Future: Buy Rating Reaffirmed Amidst Pipeline Progress and Upcoming R&D Insights
InflaRx Buy Rating: Strong Financials and High Potential of Gohibic for PG Treatment
IFRX Stock Earnings: InflaRx Beats EPS, Misses Revenue for Q1 2024
InflaRx N.V. Reports Q1 2024 Financial Loss
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update